Specialty Pharmacy

Three genes may increase the risk of breast and ovarian cancers in patients with BRCA mutations.

Ron Lanton III, Esq., President, True North Political Solutions, discusses the significant differences between biosimilars and generic drugs.

Top news of the day from across the health care landscape.

A majority of patients with hepatitis C experience disorders outside of the liver that are related to the virus.

Children with rheumatic diseases may experience treatment variability.

A novel Mcl-1 protein inhibitor may encourage cancer cell apoptosis.

Analytical treatment interruption may not cause long-term damage to patients with HIV.

A combination VEGFR-2 inhibitor plus an anti–PD-L1 agent demonstrated antitumor activity in patients with previously treated advanced gastric or gastroesophageal junction adenocarcinoma.

Cabometyx found to improve median overall survival by 2.2 months in patients with previously treated advanced hepatocellular carcinoma.

Brandon Newman, PharmD, CSP, Program Director, Vanderbilt Specialty Pharmacy, discusses why clinical outcomes data are important for specialty pharmacies.

Median progression-free survival was 5.8 months among patients with HER2-positive gastric cancer who were treated with DS-8201.

Top news of the day from the health care landscape.

A look at last week's top stories in the world of pharmacy.

Top news of the week from Specialty Pharmacy Times.

The unemployment rate for pharmacists is only 2%, according to the US News & World Report.

Clinical trial data that leads to FDA approvals may be difficult for the general public to understand.

Pembrolizumab (Keytruda) combination therapy may improve outcomes for patients with metastatic non-small cell lung cancer.

The presence of certain bacteria may enhance response to PD-1 inhibitors in melanoma.

Once-weekly pill has the potential to prevent 20% of new HIV infections.

Nearly all people who inject drugs with hepatitis C virus achieved a sustained virologic response at 12 weeks.

Mitochondrial inhibitors may be a beneficial add-on therapy for glioblastoma containing gene fusion.

Top news of the day from across the health care landscape.

Americans to walk, bike or run 7,000 miles during February bringing awareness to 7,000 rare diseases affecting 30 million Americans.

Insurers place more prior authorization requirements on PCSK9 inhibitors than other similar cholesterol treatments.

More than 60% of very elderly patients with stage 3 lung cancer did not receive treatment.

Consistent delivery of an electric field could drastically increase glioblastoma survival.

Tisagenlecleucel (Kymriah) under review to treat non-Hodgkin lymphoma and B-cell acute lymphoblastic leukemia.

An HIV protein may interact with brain cells to increase neurodegeneration.